Steinthal, Russell M.

Mr. Steinthal is a partner in the firm's New York City office. He principally works with the firm's antitrust group and has experience with the full range of the group's practice, including litigation, merger-related work, and corporate counseling.

In his time with the firm, Mr. Steinthal has been the lead antitrust attorney on a number of significant matters, including the firm's counseling of MasterCard's Board of Directors, the 2004 sale of Candle Corporation to IBM, the 2005 acquisitions of excelleRx, Inc. and RxCrossroads, LLC by Omnicare, Inc., and the 2005 private equity buyout of SunGard Data Systems. Mr. Steinthal has also worked as part of the firm's antitrust team on a variety of additional transactions involving A&P, SunGard, and Omnicare, among others.

As part of those transactions, Mr. Steinthal has helped advise clients as to the antitrust implications of their merger agreements, coordinated document review and production, and advised as to the appropriate exchange of due diligence information between competitors

Mr. Steinthal also has considerable experience preparing Hart-Scott-Rodino premerger notification forms and helps counsel companies as to the applicability of the Hart-Scott-Rodino Act to their contemplated transactions.

In 2003, Mr. Steinthal worked on the litigation team that successfully fought a hostile takeover of the Vantico Group, and was on the brief in the United States Court of Appeals for the Second Circuit. After the conclusion of the litigation, Mr. Steinthal coordinated Vantico's response to a related civil investigative demand issued by the Federal Trade Commission.

In addition to the aforementioned Hart-Scott-Rodino advice, Mr. Steinthal's corporate counseling experience includes advice to multiple clients as to pre-merger "gun-jumping," distribution issues, and unfair or deceptive trade practices.